Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-κB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapy

Hirohito Naito(Kagawa University), Mikio Sugimoto(Kagawa University)
BMC Immunology
September 25, 2025
Cited by 2


Related Papers